Utilizing Primary Research to Understand the Reimbursement Landscape

Reimbursement becomes an integral piece to any diagnostic test or procedure or medical device as you prepare for commercialization. Understanding the reimbursement landscape can become very difficult given the nuances of the different types of payers, where the product is being used, large hospital vs. clinic, in-patient vs. out-patient, POC vs. Lab Test as a few examples. As new synthetic biology platforms become more prevalent like cell and gene therapies, RNAi, MicroRNA, CircRNA, and other RNA based therapies, gene editing therapies, and other therapies that do not have reimbursement precedents set, it will become increasingly challenging to have a clear understanding of what reimbursement will look like. The best way to get the most up-to-date and accurate information is to conduct primary research.